期刊
AMERICAN JOURNAL OF TRANSPLANTATION
卷 12, 期 11, 页码 3008-3020出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1600-6143.2012.04212.x
关键词
Efficacy; everolimus; liver transplantation; reduced; tacrolimus; withdrawal
资金
- Novartis Pharma AG
- Astellas
- MSD
- Roche
- Janssen-Cilag
- Ipsen
- Eumedica
- CAF
- Novartis
- Biotest
- BMS
- Wyeth
- Quark Pharmaceuticals
- LifeCycle Pharma
- Genzyme/Sanofi
In a prospective, multicenter, open-label study, de novo liver transplant patients were randomized at day 30 +/- 5 to (i) everolimus initiation with tacrolimus elimination (TAC Elimination) (ii) everolimus initiation with reduced-exposure tacrolimus (EVR+Reduced TAC) or (iii) standard-exposure tacrolimus (TAC Control). Randomization to TAC Elimination was terminated prematurely due to a higher rate of treated biopsy-proven acute rejection (tBPAR). EVR+Reduced TAC was noninferior to TAC Control for the primary efficacy endpoint (tBPAR, graft loss or death at 12 months posttransplantation): 6.7% versus 9.7% (-3.0%; 95% CI -8.7, 2.6%; p<0.001 for noninferiority [12% margin]). tBPAR occurred in 2.9% of EVR+Reduced TAC patients versus 7.0% of TAC Controls (p = 0.035). The change in adjusted estimated GFR from randomization to month 12 was superior with EVR+Reduced TAC versus TAC Control (difference 8.50 mL/min/1.73 m(2), 97.5% CI 3.74, 13.27 mL/min/1.73 m(2), p<0.001 for superiority). Drug discontinuation for adverse events occurred in 25.7% of EVR+Reduced TAC and 14.1% of TAC Controls (relative risk 1.82, 95% CI 1.25, 2.66). Relative risk of serious infections between the EVR+Reduced TAC group versus TAC Controls was 1.76 (95% CI 1.03, 3.00). Everolimus facilitates early tacrolimus minimization with comparable efficacy and superior renal function, compared to a standard tacrolimus exposure regimen 12 months after liver transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据